Searched for
BIOSIMILARS
CPHI Milan: Beyond generics, how Indian pharma is rewriting its global playbookAt CPHI Milan, Indian pharma players are looking beyond traditional exports, using partnerships, licensing, CDMO, and differentiated produc...- When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends ...
- Last line of defence! How 7 Nifty stocks survived the market’s two-month bloodbathIn an unprecedented downturn, the Nifty has faced its longest losing streak in 25 years, sliding for over eight weeks as foreign investors ...
- Pharma sector revenue to grow 11-13 pc in FY27 on strong exports, domestic demand: CrisilIndia's pharmaceutical sector is projected to grow at 11-13 percent this fiscal year due to export increases. The domestic market is also e...
- Zydus gearing up for next phase of growth, eyeing new areas: Sharvil Patel, MD"From 2030 and beyond, we will see strong earnings from pure discovery-led business, which is our central business, our oncology business a...
- MF Tracker: HDFC Pharma & Healthcare Fund tops equity MFs at 25% in 1 year. Should investors chase the rally?HDFC Pharma and Healthcare Fund recorded an impressive 25% return in the last year, surpassing its category average across various time fra...
- Biocon arm gets positive EMA panel recommendation for breast cancerbiosimilar PebrilzoBiocon Biologics has received a positive recommendation from the European Medicines Agency’s CHMP for its Pertuzumab biosimilar, Pebrilzo, ...
- 5 stocks with consistent score improvement and upside potential of up to 22% in 1 year, according to analystsGiven the current situation both globally and domestically, one can expect more headwinds in the market. There is, on the domestic front, a...
- JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?JM Financial retained Buy ratings on Dr Reddy’s Laboratories and Aurobindo Pharma, seeing up to 28% upside over the next 12 months. The bro...
- Dr. Reddy's launches nivolumab biosimilar in IndiaDr Reddy's Laboratories has taken a significant step in cancer care with the introduction of NIVORZ, a biosimilar of nivolumab. Designed to...
- Short-term headwind? Yes. But the structure stays intact: 5 large-cap stocks with upside potential of up to 19%Wise men on the street will tell you it is foolish to try and time the market. And attempting to do so in the midst of a raging war is prob...
- Biocon shares rise 3% after Rs 638-crore block deal; Active Pine likely sellerBiocon shares rose after a block deal involving around 1.65 crore shares. Investor Active Pine was reportedly looking to sell up to 1.66 cr...
- Sandoz bets big on biosimilars, aims to double group sales by 2035Sandoz plans to more than double annual net sales by 2035, with biosimilars leading growth. The company will expand its biosimilar portfoli...
- Biocon shares: Active Pine may divest up to 1% equity worth Rs 638 crore via block dealActive Pine is likely to sell up to 1.66 crore Biocon shares, worth Rs 638 crore, through a block deal at Rs 385 per share. The development...
- Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bidRating agencies Moody's and S&P assigned investment-grade ratings to Sun Pharmaceutical Industries. This action follows Sun Pharma's propos...
- Global Market: European shares slip as oil surge fuels inflation fears; Novartis plungesEuropean shares slipped as surging oil prices raised inflation concerns amid escalating Middle East tensions and threats to Gulf energy inf...
- Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in BrazilBiocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis re...
- Biocon signs 10-year Brazil supply deal for Pertuzumab breast cancer drugIn a significant move, Biocon has secured a ten-year contract in Brazil for the distribution of Pertuzumab, made possible through its colla...
- Lupin gets USFDA approval for Modafinil tablets to treat excessive sleepinessPharmaceutical major Lupin announced its USFDA approval for Modafinil tablets. These tablets are used to treat excessive sleepiness in adul...
- Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilarCipla said its US unit has entered an exclusive partnership with China’s Qilu Pharmaceutical to license QL2107, a biosimilar of Merck’s can...
Load More
